Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $28.00 at JPMorgan Chase & Co.

Teva Pharmaceutical Industries (NYSE:TEVA) had its price objective boosted by JPMorgan Chase & Co. from $26.00 to $28.00 in a report released on Thursday,Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other research analysts have also weighed in on TEVA. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $25.86.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $24.41 on Thursday. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $25.00. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The firm has a market cap of $28.00 billion, a PE ratio of -152.56, a P/E/G ratio of 1.11 and a beta of 0.70. The business’s 50-day moving average price is $19.63 and its two-hundred day moving average price is $17.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.10. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The company had revenue of $4.48 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the prior year, the company earned $0.69 earnings per share. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.550-2.650 EPS. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors and hedge funds have recently bought and sold shares of the stock. Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $41,000. New Age Alpha Advisors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 1st quarter valued at approximately $43,000. Cromwell Holdings LLC grew its stake in shares of Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after buying an additional 629 shares in the last quarter. Sound Income Strategies LLC increased its holdings in Teva Pharmaceutical Industries by 3,715.8% during the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the last quarter. Finally, MAI Capital Management increased its holdings in Teva Pharmaceutical Industries by 26.8% during the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after buying an additional 697 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.